SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Wennborg Anders)
 

Sökning: WFRF:(Wennborg Anders) > Izokibep :

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004573naa a2200505 4500
001oai:DiVA.org:uu-503201
003SwePub
008230609s2023 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5032012 URI
0247 a https://doi.org/10.1080/19420862.2023.22099202 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Klint, Susanneu Affibody AB, Solna, Sweden.4 aut
2451 0a Izokibep :b Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
264 1b Taylor & Francis,c 2023
338 a electronic2 rdacarrier
520 a Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatment with monoclonal antibodies (mAbs) against IL-17A provides an improvement in the Psoriasis Area and Severity Index compared to conventional systemic agents. In this study, the Affibody(CIRCLED LATIN CAPITAL LETTER R) technology was used to identify and optimize a novel, small, biological molecule comprising three triple helical affinity domains, izokibep (previously ABY-035), for the inhibition of IL-17A signaling. Preclinical studies show that izokibep, a small 18.6 kDa IL-17 ligand trap comprising two IL-17A-specific Affibody domains and one albumin-binding domain, selectively inhibits human IL-17A in vitro and in vivo with superior potency and efficacy relative to anti-IL-17A mAbs. A Phase 1 first-in-human study was conducted to establish the safety, pharmacokinetics, and preliminary efficacy of izokibep, when administered intravenously and subcutaneously as single doses to healthy subjects, and as single intravenous and multiple subcutaneous doses to patients with psoriasis (NCT02690142; EudraCT No: 2015-004531-13). Izokibep was well tolerated with no meaningful safety concerns identified in healthy volunteers and patients with psoriasis. Rapid efficacy was seen in all psoriasis patients after one dose which further improved in patients receiving multiple doses. A therapeutic decrease in joint pain was also observed in a single patient with concurrent psoriatic arthritis. The study suggests that izokibep has the potential to safely treat IL17A-associated diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Dermatologi och venereologi0 (SwePub)302042 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Dermatology and Venereal Diseases0 (SwePub)302042 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a ABY-035
653 a first-in-human
653 a IL-17A inhibition
653 a izokibep
653 a psoriasis
7001 a Feldwisch, Joachimu Affibody AB, Solna, Sweden.4 aut
7001 a Gudmundsdotter, Lindviu Affibody AB, Solna, Sweden.4 aut
7001 a Bergstedt, Karin Dillneru Affibody AB, Solna, Sweden.4 aut
7001 a Gunneriusson, Elinu Affibody AB, Solna, Sweden.4 aut
7001 a Guthenberg, Ingmarie Hoidenu Affibody AB, Solna, Sweden.4 aut
7001 a Wennborg, Andersu Affibody AB, Solna, Sweden.4 aut
7001 a Nyborg, Andrew C. C.u ACELYRIN, Agoura Hills, CA USA.4 aut
7001 a Kamboj, Amol P. P.u ACELYRIN, Agoura Hills, CA USA.4 aut
7001 a Peloso, Paul M. M.u ACELYRIN, Agoura Hills, CA USA.4 aut
7001 a Bejker, Davidu Affibody AB, Solna, Sweden.4 aut
7001 a Frejd, Fredrik Y.u Uppsala universitet,Cancerprecisionsmedicin,Affibody AB, Solna, Sweden.;Affibody AB, Scheeles vag 2, SE-17165 Solna, Sweden.4 aut0 (Swepub:uu)freni195
7102 a Affibody AB, Solna, Sweden.b ACELYRIN, Agoura Hills, CA USA.4 org
7730 t mAbsd : Taylor & Francisg 15:1q 15:1x 1942-0862x 1942-0870
8564 u https://uu.diva-portal.org/smash/get/diva2:1764718/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-503201
8564 8u https://doi.org/10.1080/19420862.2023.2209920

Hitta via bibliotek

  • mAbs (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy